Dr. Stuart Himmelstein evaluates non-surgical considerations in peripheral neuropathy

Dr. Stuart Himmelstein, DC, a Philadelphia-based chiropractor, examines how peripheral neuropathy is evaluated in ...

Dr. Stuart Himmelstein reviews clinical distinctions between neuropathy and circulation-related leg symptoms

Dr. Stuart Himmelstein, DC, a Philadelphia-based chiropractor, examines how clinicians differentiate between peripheral ...
KFGO

Intellia gets FDA nod to resume one gene therapy trial after safety pause

Intellia Therapeutics said on Tuesday that the U.S. drug regulator has lifted a clinical hold on one of its late-stage gene ...
Medical Dialogues

Vitamin B12 Supplementation Improves neuropathic pain in Diabetic Peripheral Neuropathy, suggests research

In a new study, researchers found that among patients with diabetic peripheral neuropathy (DPN) and low serum vitamin B12 ...

Intellia gets FDA nod to resume gene therapy trial after safety pause

Intellia Therapeutics said on Tuesday that the U.S. drug regulator has lifted a clinical hold on one of its late-stage gene therapy trials, allowing the company to resume testing its experimental drug ...

Man, 26, euthanised because he was diabetic and blind

Kiano Vafaeian, 26, had type 1 diabetes, partial blindness and depression, but was approved for the government euthanasia ...
Investor's Business Daily on MSN

The gene-editing news that sent beleaguered Intellia Therapeutics stock up

Intellia Therapeutics stock surged Tuesday after the FDA aid it would allow the company to restart a gene-editing study.
The Manila Times

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 ...
Fierce Biotech

After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia's CRISPR therapy

The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial. Shortly after the regulatory hold was implemented, Intellia disclosed that ...
BioSpace

FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.

Family distraught after Canadian doctor euthanized man, 26, because he was diabetic and blind

A Canadian family has been left heartbroken and angry after Kiano Vafaeian, a 26-year-old diabetic and blind man, died of ...
Le Lézard

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and ...